Can a common diabetes pill protect the heart? new trial aims to find out.

NCT ID NCT07288749

Not yet recruiting Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 25, 2026 · Updated 20 times

Summary

This study tests whether glimepiride, a standard diabetes medication, can reduce the risk of heart-related death, heart transplant, or worsening heart failure in people with type 2 diabetes and chronic heart failure. About 1,484 adults aged 18-80 will receive either glimepiride or a placebo, and researchers will track their heart health over time. The goal is to see if this drug offers added heart protection beyond blood sugar control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tongji Hostipal

Wuhan, Hubei, 430030, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHRONIC HEART FAILURE (CHF) TYPE 2 DIABETES MELLITUS (T2DM)